Our study details the molecular mechanism of the Cobll1/PACSIN2/SH3BP1 pathway in regulating drug resistance in CML and presents a potential pharmacological target to overcome TKI resistance and BC progression in CML. Here, PACSIN2 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.